User profiles for M. Martini

Miriam Martini

PhD, Università degli Studi di Torino
Verified email at unito.it
Cited by 9170

PI3K/AKT signaling pathway and cancer: an updated review

M Martini, MC De Santis, L Braccini, F Gulluni… - Annals of …, 2014 - Taylor & Francis
Despite development of novel agents targeting oncogenic pathways, matching targeted
therapies to the genetic status of individual tumors is proving to be a daunting task for clinicians. …

[HTML][HTML] How big data and artificial intelligence can help better manage the COVID-19 pandemic

…, H Dai, G Damiani, M Behzadifar, M Martini… - International journal of …, 2020 - mdpi.com
SARS-CoV2 is a novel coronavirus, responsible for the COVID-19 pandemic declared by the
World Health Organization. Thanks to the latest advancements in the field of molecular and …

[HTML][HTML] Plausible mechanisms for the protectiveness of whole grains

JL Slavin, MC Martini, DR Jacobs Jr… - The American journal of …, 1999 - Elsevier
Dietary guidelines recommend the consumption of whole grains to prevent chronic diseases.
Epidemiologic studies support the theory that whole grains are protective against cancer, …

Gut microbiota from twins discordant for obesity modulate metabolism in mice

…, K Funai, DK Hayashi, BJ Lyle, MC Martini… - Science, 2013 - science.org
… We recruited four twin pairs, discordant for obesity (obese twin BMI > 30 kg/m 2 ) with a
sustained multiyear BMI difference of ≥5.5 kg/m 2 (n = 1 MZ and 3 DZ pairs) (Fig. 1A). Fecal …

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

F Di Nicolantonio, M Martini, F Molinari… - Journal of clinical …, 2008 - air.unimi.it
Purpose: Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% …

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a …

…, F Molinari, P Saletti, S De Dosso, M Martini… - The lancet …, 2010 - thelancet.com
Background Following the discovery that mutant KRAS is associated with resistance to anti-epidermal
growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

A new measurement of direct CP violation in two pion decays of the neutral kaon

…, M Martini, F Petrucci, M Savrie, A Bizzeti, M Calvetti… - Physics Letters B, 1999 - Elsevier
The NA48 experiment at CERN has performed a new measurement of direct CP violation,
based on data taken in 1997 by simultaneously collecting K L and K S decays into π 0 π 0 and …

[PDF][PDF] Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis

…, DA Toledo-Teixeira, PL Parise, MC Martini… - Cell metabolism, 2020 - cell.com
COVID-19 can result in severe lung injury. It remained to be determined why diabetic individuals
with uncontrolled glucose levels are more prone to develop the severe form of COVID-…

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

…, M Martini, F Molinari, S Veronese, M Nichelatti… - Cancer research, 2009 - AACR
The monoclonal antibodies (moAb) panitumumab and cetuximab target the epidermal growth
factor receptor (EGFR) and have proven valuable for the treatment of metastatic colorectal …

[HTML][HTML] A precision measurement of direct CP violation in the decay of neutral kaons into two pions

…, M Martini, L Masetti, F Petrucci, M Savrie, M Scarpa… - Physics Letters B, 2002 - Elsevier
The direct CP violation parameter Re(ϵ′/ϵ) has been measured from the decay rates of
neutral kaons into two pions using the NA48 detector at the CERN SPS. The 2001 running …